$1.240
-0.039 (-3.13%)Zum Schluss
NNVC-News
NNVC-Events
Selling Stockholders Plan to Sell 2.52M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.52M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
NanoViricides Receives Approval for NV-387 Clinical Trial in DRC
NanoViricides received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the local regulatory agency ACOREP in the Democratic Republic of Congo. NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well known University in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebola viruses in DRC. The Principal Investigator sent in the application for the clinical trial to ACOREP which has now been approved. The PI, with the DRC team, has already been performing initial preparations in anticipation of the clinical trial approval, in order to speed up the date to the first dosing of patients.
NanoViricides Awaits Approval for NV-387 Oral Gummies Phase II Trial
The company said, "NanoViricides is eagerly awaiting regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies, after having filed an application to the local regulatory agency ACOREP, as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo. The Company explains that it has already raised the financing to support this clinical trial."
NanoViricides Enters Agreement for $3.8M Financing with Institutional Investor
NanoViricides entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock, together with accompanying warrants to purchase 2,516,339 shares of common stock for gross proceeds of approximately $3.8M in a registered direct offering. The common shares are being sold in combination with an accompanying full warrant. Each whole warrant has an exercise price of $1.75 per share and will expire five and half years from the date of issuance. D. Boral Capital is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about July 27, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of ~$3.8M from the Offering, before deducting placement agent fees and other related expenses.
NanoViricides Seeks Approval for Phase II Trial of NV-387
NanoViricides has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo. NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well known University in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebolaviruses in DRC. The Principal Investigator has sent in the application for the clinical trial. Om Sai is also the CRO leading the Company's Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox in DRC.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.